These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11794436)

  • 1. Major bleeding caused by warfarin in a genetically susceptible patient.
    Bloch A; Ben-Chetrit E; Muszkat M; Caraco Y
    Pharmacotherapy; 2002 Jan; 22(1):97-101. PubMed ID: 11794436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of cytochrome P450 2C9 polymorphism on warfarin metabolism and dosing.
    Redman AR
    Pharmacotherapy; 2001 Feb; 21(2):235-42. PubMed ID: 11213860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.
    Taube J; Halsall D; Baglin T
    Blood; 2000 Sep; 96(5):1816-9. PubMed ID: 10961881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy.
    Furuya H; Fernandez-Salguero P; Gregory W; Taber H; Steward A; Gonzalez FJ; Idle JR
    Pharmacogenetics; 1995 Dec; 5(6):389-92. PubMed ID: 8747411
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reply to rebuttal: Gene variants of the cytochrome P450 CYP2C9 affect oral anticoagulation with warfarin.
    Margaglione M; Brancaccio V; Ciampa A; Di Minno G
    Thromb Haemost; 2001 Sep; 86(3):938. PubMed ID: 11583336
    [No Abstract]   [Full Text] [Related]  

  • 11. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers.
    Verstuyft C; Morin S; Robert A; Loriot MA; Beaune P; Jaillon P; Becquemont L
    Pharmacogenetics; 2001 Nov; 11(8):735-7. PubMed ID: 11692083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
    Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele.
    Ablin J; Cabili S; Lagziel A; Peretz H
    Isr Med Assoc J; 2002 Feb; 4(2):139-41. PubMed ID: 11875991
    [No Abstract]   [Full Text] [Related]  

  • 14. Interindividual variability in sensitivity to warfarin--Nature or nurture?
    Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
    Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2C9 polymorphism and warfarin dose requirements.
    Daly AK; Day CP; Aithal GP
    Br J Clin Pharmacol; 2002 Apr; 53(4):408-9. PubMed ID: 11966680
    [No Abstract]   [Full Text] [Related]  

  • 16. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin.
    Tabrizi AR; Zehnbauer BA; Borecki IB; McGrath SD; Buchman TG; Freeman BD
    J Am Coll Surg; 2002 Mar; 194(3):267-73. PubMed ID: 11893129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic control of anticoagulation.
    Mannucci PM
    Lancet; 1999 Feb; 353(9154):688-9. PubMed ID: 10073506
    [No Abstract]   [Full Text] [Related]  

  • 18. CYP2C9*3 allelic variant and bleeding complications.
    Ogg MS; Brennan P; Meade T; Humphries SE
    Lancet; 1999 Sep; 354(9184):1124. PubMed ID: 10509530
    [No Abstract]   [Full Text] [Related]  

  • 19. Possible interaction between warfarin and Lycium barbarum L.
    Lam AY; Elmer GW; Mohutsky MA
    Ann Pharmacother; 2001 Oct; 35(10):1199-201. PubMed ID: 11675844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic association between sensitivity to warfarin and expression of CYP2C9*3.
    Steward DJ; Haining RL; Henne KR; Davis G; Rushmore TH; Trager WF; Rettie AE
    Pharmacogenetics; 1997 Oct; 7(5):361-7. PubMed ID: 9352571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.